S&P 500 7,609.78 +0.13% NASDAQ 27,093.90 +0.03% DOW 51,307.79 +0.45% R2K 2,931.96 +0.90% VIX 15.77 -1.74%
N
ABBV AbbVie Inc. NYQ
$215.40 +2.47 (+1.16%)
Neutral · +0.64σ

132-Day TAO Zones

21 EMA +1 ATR +2 ATR −2 ATR
O H L C

Key statistics

Mkt cap $380.6B
P/E ttm 105.6
Fwd P/E 13.3
Beta 0.30
Day range $215.40
52w range $190.75 – $237.11
Avg vol 6.6M
RSI(2) 53.0
ROE
Net mgn 5.8%
FCF mgn 33.1%
Debt/Eq
Div yld 325.00%
Sector Healthcare
Industry Drug Manufacturers - General
Next earn 2026-07-30

Matrix setup grades

Long
score 22 · tech 22 / 80 · support 0 / 20
above KC1 lower, +0.61 ATR from EMA21 · bullish engulfing
  • · Bullish engulfing — body fully covers prior red bar
Short
score 12 · tech 12 / 80 · support 0 / 20
below KC1 upper, +0.61 ATR from EMA21 · no notable pattern
  • · Aligned with weak downtrend

Options · swing

See more →
CALL $220 2026-07-17
$6.45
PUT $220 2026-07-17
$11.22

Insider activity

See more →

No Form 4 filings in the last 30 days.

Earnings

See more →
Last reported
2026-04-29
EPS (act / est)
2.65 / 2.67
Surprise
-0.8%
Next report
2026-07-30

About

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere…